SynapCell

SynapCell is a France-based brain-focused biotechnology company established in 2005 with a focus on identifying effective drug candidates within the brain using quantitative, EEG-based methods. The company offers drug developers robust and unbiased endpoints on drug efficacy in vivo during the preclinical stage, covering a wide array of capabilities including dose-response studies, pharmacodynamics, biomarker identification, disease-modifying assays, and model phenotyping. SynapCell's expertise in neuroscience extends to conditions such as Epilepsy, Parkinson's disease, Essential Tremors, and schizophrenia-related information processing defects. Since its inception, SynapCell has garnered a unique reputation in the market, attracting returning customers from the USA, Japan, Korea, and Europe, forming the basis for long-lasting successful business partnerships. Notably, the last investment standing at $4.43M was secured during the Series A round on 06 March 2009 with the participation of Grenoble Angels - Oser l'entreprise, Expansinvest, Rhone-Alpes Creation, VIADUC 8. This investment bolsters SynapCell's position as a promising player in the biotechnology, healthcare, and pharmaceutical industries, underlining its potential for growth and innovation.